John Kuruvilla

John Kuruvilla

Biography

A clinician investigator and malignant hematologist, Dr. Kuruvilla’s scholarly activities are focused on the development of novel therapies for patients with relapsed and refractory Hodgkin’s and non-Hodgkin’s lymphomas. His work has been important in providing evidence through clinical trials for the efficacy of a number of therapies in these conditions. His work has influenced both clinical practice guidelines and regulatory approvals. He was lead author on a confirmatory phase 3 trial of the immunotherapy Pembrolizumab (a checkpoint inhibitor) in relapsed/refractory Hodgkin’s lymphoma, published in Lancet Oncology.

Dr. Kuruvilla he has given ~ 40 invited presentations, including in Korea, Uruguay, Italy, Kuwait, the United States, Malaysia, the United Kingdom, Germany, China, India, Denmark, and Brazil. He is an invited Member of the Lymphoma Steering Committee for the National Cancer Institute (US), which is responsible for collaboration between the North American cancer cooperative groups.